Department of Radiation Oncology, College of Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, 56, Dongsuro, Bupyung-gu, Incheon, 21431, Republic of Korea.
Clin Transl Oncol. 2024 Mar;26(3):689-697. doi: 10.1007/s12094-023-03283-6. Epub 2023 Aug 4.
We investigated the effect of boost radiation therapy (RT) in addition to whole pelvis RT (WPRT) on treatment outcome and safety of cervical cancer patients following hysterectomy with close/positive resection margins (RM).
We retrospectively analyzed 51 patients with cervical cancer who received WPRT with or without boost-RT as adjuvant treatment between July 2006 and June 2022. Twenty patients (39.2%) were treated with WPRT-alone, and 31 (60.8%) received boost-RT after WPRT using brachytherapy or intensity-modulated RT.
The median follow-up period was 41 months. According to RT modality, the 4-year local control (LC) and locoregional control (LRC) rates of patients treated with WPRT-alone were 61% and 61%, respectively, whereas those in LC and LRC rates in patients who underwent WPRT with boost-RT were 93.2% and 75.3%, with p-values equal to 0.005 and 0.090, respectively. Seven patients (35.0%) had local recurrence in the WPRT-treated group compared to only two out of the 31 patients (6.5%) in the WPRT with boost-RT-treated counterparts (p = 0.025). Boost-RT was a significantly good prognostic factor for LC (p = 0.013) and LRC (p = 0.013). Boost-RT did not result in statistically-significant improvements in progression-free survival or overall survival. The acute and late toxicity rates were not significantly different between groups.
Boost RT following WPRT is a safe and effective treatment strategy to improve LC without increasing toxicity in patients with cervical cancer with close/positive RM after hysterectomy.
我们研究了在子宫切除术后切缘(RM)接近/阳性的宫颈癌患者中,加量放疗(RT)联合全骨盆放疗(WPRT)对治疗结果和安全性的影响。
我们回顾性分析了 2006 年 7 月至 2022 年 6 月间接受 WPRT 加或不加加量 RT 作为辅助治疗的 51 例宫颈癌患者。20 例(39.2%)患者接受 WPRT 治疗,31 例(60.8%)患者在 WPRT 后接受近距离放疗或调强放疗加量 RT。
中位随访时间为 41 个月。根据放疗方式,单纯 WPRT 治疗患者的 4 年局部控制(LC)和局部区域控制(LRC)率分别为 61%和 61%,而接受 WPRT 加量 RT 治疗的患者 LC 和 LRC 率分别为 93.2%和 75.3%,p 值分别为 0.005 和 0.090。单纯 WPRT 治疗组有 7 例(35.0%)患者出现局部复发,而在接受 WPRT 加量 RT 治疗的 31 例患者中仅有 2 例(6.5%)出现局部复发(p=0.025)。加量 RT 是 LC(p=0.013)和 LRC(p=0.013)的显著预后因素。加量 RT 并未显著改善无进展生存期或总生存期。两组间急性和晚期毒性发生率无显著差异。
在子宫切除术后 RM 接近/阳性的宫颈癌患者中,加量 RT 联合 WPRT 是一种安全有效的治疗策略,可提高 LC 率,而不会增加毒性。